Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer

Fig. 1

Effects of minocycline WP on rash induced by afatinib ointment application. a Left side is the TEWL value of control mice with low concentration (0.075%) afatinib WP for 7 days with/without minocycline WP treatment. Right side is high concentration (0.10%) afatinib WP treatment. b Representative images of the effects of treatment with minocycline WP after onset of the rash. Left side is low concentration (0.075%) afatinib WP, and right side is treatment with minocycline WP from 7 days after the start of administration. Data (mean ± SD, n = 4 per group) are compared by one-way analysis of variance

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us